Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IBRX with free AI briefings, catalyst countdowns, and dilution alerts.

IBRX · ImmunityBio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$334.3M Cash on Hand
14.1mo Cash Runway
31.1% Short Interest
$14.25 Analyst Target (4)
Follow IBRX by email Get an email when IBRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IBRX, unsubscribe in one click. Privacy

📣 What IBRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic Invariant Natural Killer T-cells… Community-Acquired Pneumonia (CAP) Phase 3 · NCT07492875 Withdrawn
BCG Vaccine NMIBC Phase 3 · NCT07551544 Withdrawn
Nab-paclitaxel Non Small Cell Lung Cancer Phase 3 · NCT03520686 Terminated
Cisplatin or Carboplatin NSCLC (Advanced Non-small Cell Lung Cancer) Phase 3 · NCT07524257 Withdrawn
Nogapendekin Alfa Inbakicept (N-803) Non Small Cell Lung Cancer Phase 3 · NCT03520686 Terminated
Drug: Nogapendekin alfa inbakicept (NAI) NSCLC (Advanced Non-small Cell Lung Cancer) Phase 3 · NCT07524257 Withdrawn
Nab-paclitaxel (squamous) OR Pemetrexed… NSCLC (Advanced Non-small Cell Lung Cancer) Phase 3 · NCT07524257 Withdrawn
Nab-paclitaxel OR Paclitaxel OR Docetaxel… NSCLC (Advanced Non-small Cell Lung Cancer) Phase 3 · NCT07524257 Withdrawn
Prior failed checkpoint inhibitor NSCLC Stage IV Phase 3 · NCT06745908 Recruiting
Fluorouracil Pancreatic Cancer Phase 2 · NCT04390399 Active not recruiting
5Fluorouracil (5-FU) Urothelial Carcinoma Phase 1/2 · NCT03197571 Withdrawn
AAHI-SC2 Vaccine COVID-19 Phase 1/2 · NCT05370040 Terminated
AAHI-SC3 Vaccine COVID-19 Phase 1/2 · NCT05370040 Terminated
Aldoxorubicin HCl Pancreatic Cancer Phase 2 · NCT04390399 Active not recruiting
Aldoxorubicin Hydrochloride Chordoma Phase 1/2 · NCT03647423 Withdrawn
Allogeneic invariant Natural Killer T (iNKT)… Acute Respiratory Distress Syndrome Phase 2 · NCT07492888 Withdrawn

Also used in these trials (approved or third-party drugs, not IBRX's own candidates): Bevacizumab, Cisplatin, Docetaxel Anhydrous, Carboplatin, Pembrolizumab, Pemetrexed Disodium, Tislelizumab, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, Durvalumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IBRX holds $334.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $70.9M/quarter from operations, an estimated runway of 14.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IBRX files for a raise →

👥 Who Owns IBRX

Insiders 70.4% Institutions (516 holders) 20.5% Public and other holders 9.1%
HolderTypeShares% of sharesAs of
Patrick Soon-shiong
Founder, Executive Chairman, Global Chie · +4.12M options
Insider 745,518,285 70.08% 2026-07-31
Blackrock Inc. Institution (13F) 36,123,813 3.40% 2026-09-30
State Street Corporation Institution (13F) 21,095,418 1.98% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 19,390,126 1.82% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 18,804,937 1.77% 2026-09-30
Shaw D.E. & Co., Inc. Institution (13F) 10,711,868 1.01% 2026-09-30
Geode Capital Management, LLC Institution (13F) 10,606,654 1.00% 2026-09-30
Two Sigma Investments, LP Institution (13F) 5,831,161 0.55% 2026-09-30
Charles Schwab Investment Management, In Institution (13F) 4,934,258 0.46% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 4,129,906 0.39% 2026-09-30
UBS Group AG Institution (13F) 3,775,302 0.35% 2026-09-30
Barry J. Simon
Director · +174,391 options
Insider 2,777,788 0.26% 2026-10-05

Share count 1,063,826,073 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-05
filed 2026-10-06
Simon Barry J.
Sale (S) 25,000 $10.75 2,777,788
2026-10-02
filed 2026-10-06
Cohen Cheryl
Option exercise (M) 55,979 $2.98 181,365
2026-10-02
filed 2026-10-06
Cohen Cheryl
Sale (S) 81,056 $10.50 100,309
2026-10-02
filed 2026-10-06
Cohen Cheryl
Option exercise (M) 55,979 – –
2026-07-02
filed 2026-07-06
Cohen Cheryl
Sale (S) 131,210 $9.50 125,386

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-10-14 ANKTIVA sBLA +17.1% +1.1% —

Browse all historical PDUFA outcomes →

Get the full IBRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IBRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.